Skip to main content
Erschienen in: Tumor Biology 6/2015

01.06.2015 | Research Article

Significance of Trask protein interactions in brain metastatic cohorts of lung cancers

verfasst von: Hua Wu, Li-qun Shang, Rui-lin Chen, Shu-mei Yang, Shui-li Wang, Jun Wang, Gang Sun

Erschienen in: Tumor Biology | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

A class of adhesion protein that occurs in the membrane with both extracellular and intracellular domain and play vital role in maintaining multicellularity is TRASK, also called CUB-domain containing protein1, CD318 (CDCP1). Specifically, in the current study, documented aggressive grades of lung cancers and distant metastatic tissues were examined for protein interactions of Trask and compared with lung cancer variants in situ. The intracellular domain of Trask has the ability to undergo tyrosine phosphorylation and thereafter undergo increased genomic expression, as well as interact with cytoskeletal proteins in the cell periphery and other local signal transduction machinery to induce invadopodia formation and distant metastasis. We incorporated proximity ligation assay to examine protein interactions of Trask in metastatic lung cancer tissues and compare with advanced and low-grade lung cancers restricted to the primary site of origins. Here, we provide direct evidence that activated Trask, which is a phosphorylated form, binds with cytoskeletal proteins actin and spectrin. These interactions were not seen in locally growing lung cancer and cancer in situ. These interactions may be responsible for invadopodia formation and breaking free from a multicellular environment. Functional studies demonstrated interaction between Trask and the STOCs Orai1 and Stim1. Calcium release from internal stores was highest in metastatic lung cancers, suggesting this mechanism as an initial stimulus for the cells to respond chaotically to external growth factor stimulation, especially in aggressive metastatic variants of lung cancers. Recently, inhibitors of STOCs have been identified, and preclinical evidence may be obtained whether these drugs may be of benefit in preventing the deadly consequences of lung cancer.
Literatur
1.
Zurück zum Zitat Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries LA, Lewis DR. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120 Suppl 23:3781–92.CrossRefPubMedPubMedCentral Chen VW, Ruiz BA, Hsieh MC, Wu XC, Ries LA, Lewis DR. Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014;120 Suppl 23:3781–92.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat El-Sherief AH, Lau CT, Wu CC, Drake RL, Abbott GF, Rice TW. International association for the study of lung cancer (IASLC) lymph node map: radiologic review with CT illustration. Radiographics. 2014;34:1680–91.CrossRefPubMed El-Sherief AH, Lau CT, Wu CC, Drake RL, Abbott GF, Rice TW. International association for the study of lung cancer (IASLC) lymph node map: radiologic review with CT illustration. Radiographics. 2014;34:1680–91.CrossRefPubMed
3.
Zurück zum Zitat Oyewumi MO, Alazizi A, Wehrung D, Manochakian R, Safadi FF. Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol. 2014;2014:236246.CrossRefPubMedPubMedCentral Oyewumi MO, Alazizi A, Wehrung D, Manochakian R, Safadi FF. Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. Int J Cell Biol. 2014;2014:236246.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Huang Q, Ouyang X. Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions. Cancer Epidemiol. 2013;37:703–7.CrossRefPubMed Huang Q, Ouyang X. Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions. Cancer Epidemiol. 2013;37:703–7.CrossRefPubMed
5.
Zurück zum Zitat Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8:344–56.PubMedPubMedCentral Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain RK. The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol. 2011;8:344–56.PubMedPubMedCentral
6.
Zurück zum Zitat Krishnan K, Khanna C, Helman LJ. The molecular biology of pulmonary metastasis. Thorac Surg Clin. 2006;16:115–24.CrossRefPubMed Krishnan K, Khanna C, Helman LJ. The molecular biology of pulmonary metastasis. Thorac Surg Clin. 2006;16:115–24.CrossRefPubMed
7.
Zurück zum Zitat Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004;45 Suppl 2:S253–7.CrossRefPubMed Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004;45 Suppl 2:S253–7.CrossRefPubMed
8.
Zurück zum Zitat Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep. 2001;3:467–75.CrossRefPubMed Puduvalli VK. Brain metastases: biology and the role of the brain microenvironment. Curr Oncol Rep. 2001;3:467–75.CrossRefPubMed
9.
Zurück zum Zitat Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev. 1993;12:325–43.CrossRefPubMed Nicolson GL. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metastasis. Cancer Metastasis Rev. 1993;12:325–43.CrossRefPubMed
10.
Zurück zum Zitat D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6:101–14.CrossRefPubMedPubMedCentral D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6:101–14.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–66.CrossRefPubMed Wood SL, Pernemalm M, Crosbie PA, Whetton AD. The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev. 2014;40:558–66.CrossRefPubMed
12.
Zurück zum Zitat Yamanaka R. Medical management of brain metastases from lung cancer (review). Oncol Rep. 2009;22:1269–76.CrossRefPubMed Yamanaka R. Medical management of brain metastases from lung cancer (review). Oncol Rep. 2009;22:1269–76.CrossRefPubMed
13.
Zurück zum Zitat Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol. 2012;83:305–14.CrossRefPubMed Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol. 2012;83:305–14.CrossRefPubMed
15.
Zurück zum Zitat Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Investig. 2014;61:241–53.CrossRef Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y. The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Investig. 2014;61:241–53.CrossRef
16.
Zurück zum Zitat Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73:1168–79.CrossRefPubMed Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73:1168–79.CrossRefPubMed
17.
18.
Zurück zum Zitat Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009;174:1756–65.CrossRefPubMedPubMedCentral Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009;174:1756–65.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, et al. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011;31:766–82.CrossRefPubMed Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, et al. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011;31:766–82.CrossRefPubMed
20.
Zurück zum Zitat Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009;15:2311–22.CrossRefPubMedPubMedCentral Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, et al. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009;15:2311–22.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74:5229–43.CrossRefPubMed Lin CY, Chen HJ, Huang CC, Lai LC, Lu TP, Tseng GC, et al. ADAM9 promotes lung cancer metastases to brain by a plasminogen activator-based pathway. Cancer Res. 2014;74:5229–43.CrossRefPubMed
22.
Zurück zum Zitat Hansen MC, Nederby L, Henriksen MO, Hansen M, Nyvold CG. Sensitive ligand-based protein quantification using immuno-PCR: a critical review of single-probe and proximity ligation assays. Biotechniques. 2014;56:217–28.CrossRefPubMed Hansen MC, Nederby L, Henriksen MO, Hansen M, Nyvold CG. Sensitive ligand-based protein quantification using immuno-PCR: a critical review of single-probe and proximity ligation assays. Biotechniques. 2014;56:217–28.CrossRefPubMed
23.
Zurück zum Zitat Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, et al. Protein biomarker validation via proximity ligation assays. Biochim Biophys Acta. 1844;2014:933–9. Blokzijl A, Nong R, Darmanis S, Hertz E, Landegren U, et al. Protein biomarker validation via proximity ligation assays. Biochim Biophys Acta. 1844;2014:933–9.
24.
Zurück zum Zitat Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Exp Rev Proteom. 2010;7:401–9.CrossRef Weibrecht I, Leuchowius KJ, Clausson CM, Conze T, Jarvius M, Howell WM, et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Exp Rev Proteom. 2010;7:401–9.CrossRef
25.
Zurück zum Zitat Takkunen M, Hukkanen M, Liljeström M, Grenman R, Virtanen I. Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia. J Cell Mol Med. 2010;14:1569–93.CrossRefPubMed Takkunen M, Hukkanen M, Liljeström M, Grenman R, Virtanen I. Podosome-like structures of non-invasive carcinoma cells are replaced in epithelial-mesenchymal transition by actin comet-embedded invadopodia. J Cell Mol Med. 2010;14:1569–93.CrossRefPubMed
26.
Zurück zum Zitat Sun J, Lu F, He H, Shen J, Messina J, Mathew R, et al. STIM1- and Orai1-mediated Ca2+ oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol. 2014;207:535–48.CrossRefPubMedPubMedCentral Sun J, Lu F, He H, Shen J, Messina J, Mathew R, et al. STIM1- and Orai1-mediated Ca2+ oscillation orchestrates invadopodium formation and melanoma invasion. J Cell Biol. 2014;207:535–48.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7.CrossRefPubMedPubMedCentral Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A. 2008;105:692–7.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Murai R, Tanaka M, Takahashi Y, Kuribayashi K, Kobayashi D, Watanabe N. Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K. Clin Exp Metastasis. 2014;31:787–94.CrossRefPubMed Murai R, Tanaka M, Takahashi Y, Kuribayashi K, Kobayashi D, Watanabe N. Stanniocalcin-1 promotes metastasis in a human breast cancer cell line through activation of PI3K. Clin Exp Metastasis. 2014;31:787–94.CrossRefPubMed
29.
Zurück zum Zitat Sheridan JT, Gilmore RC, Watson MJ, Archer CB, Tarran R. 17β-Estradiol inhibits phosphorylation of stromal interaction molecule 1 (STIM1) protein: implication for store-operated calcium entry and chronic lung diseases. J Biol Chem. 2013;288:33509–18.CrossRefPubMedPubMedCentral Sheridan JT, Gilmore RC, Watson MJ, Archer CB, Tarran R. 17β-Estradiol inhibits phosphorylation of stromal interaction molecule 1 (STIM1) protein: implication for store-operated calcium entry and chronic lung diseases. J Biol Chem. 2013;288:33509–18.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Wang F, Liu DZ, Xu H, Li Y, Wang W, Liu BL, et al. Thapsigargin induces apoptosis by impairing cytoskeleton dynamics in human lung adenocarcinoma cells. Sci World J. 2014;2014:619050. Wang F, Liu DZ, Xu H, Li Y, Wang W, Liu BL, et al. Thapsigargin induces apoptosis by impairing cytoskeleton dynamics in human lung adenocarcinoma cells. Sci World J. 2014;2014:619050.
31.
Zurück zum Zitat Hirooka S, Akashi T, Ando N, Suzuki Y, Ishida N, Kurata M, et al. Localization of the invadopodia-related proteins actinin-1 and cortactin to matrix-contact-side cytoplasm of cancer cells in surgically resected lung adenocarcinomas. Pathobiology. 2011;78:10–23.CrossRefPubMed Hirooka S, Akashi T, Ando N, Suzuki Y, Ishida N, Kurata M, et al. Localization of the invadopodia-related proteins actinin-1 and cortactin to matrix-contact-side cytoplasm of cancer cells in surgically resected lung adenocarcinomas. Pathobiology. 2011;78:10–23.CrossRefPubMed
32.
Zurück zum Zitat Wang S, Li E, Gao Y, Wang Y, Guo Z, He J, et al. Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device. PLoS One. 2013;8:e56448.CrossRefPubMedPubMedCentral Wang S, Li E, Gao Y, Wang Y, Guo Z, He J, et al. Study on invadopodia formation for lung carcinoma invasion with a microfluidic 3D culture device. PLoS One. 2013;8:e56448.CrossRefPubMedPubMedCentral
Metadaten
Titel
Significance of Trask protein interactions in brain metastatic cohorts of lung cancers
verfasst von
Hua Wu
Li-qun Shang
Rui-lin Chen
Shu-mei Yang
Shui-li Wang
Jun Wang
Gang Sun
Publikationsdatum
01.06.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3053-7

Weitere Artikel der Ausgabe 6/2015

Tumor Biology 6/2015 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.